A new experimental study by Nyack Hospital's Clinical Pharmacy Manager finds racial differences in the optimal dosing of the antibiotic doripenem in critically ill patients. The study, led by Andras Farkas, PharmD., suggests the need for more aggressive dosing of the drug in patients of Hispanic descent.
The findings will be presented at the Infectious Disease Society of America Annual Meeting, held in San Francisco from October 2-6, 2013, by Nyack infectious disease specialist Dr. Kenneth Rowin.
Doripenem (Doribax) is used as a last line of therapy against the most resistant organisms, Dr. Farkas says. The drug, used frequently at Nyack Hospital, is given to treat serious infections of the urinary tract, kidney, and abdomen that are often caused by multi-drug resistant bacteria.
The drug is administered intravenously, and is cleared through the kidneys before the body eliminates it. A study published in 2010, which provided the basis of this experiment at Nyack Hospital, suggested there might be racial differences in how quickly the drug was cleared. "This is very important, because the clearance rate affects the concentration of the drug in the blood," he says. "We want to maintain a certain concentration in the blood, and if you have a faster clearance, concentrations are lower than the body needs."
As a result of his findings, Dr. Farkas recommends that if patients of Hispanic descent don't respond to the dose of doripenem they are given, doctors should consider a different dosing strategy, such as extending the infusion time or increasing the dose, depending on the organism being treated.
It is not known why Hispanics clear doripenem out of their system faster than people of other groups, Dr. Farkas noted.
Register here For more information & diplomas
Contacts: 9 abbas el-akkad street, nassr city, Cairo, Egypt
Tel: (+202) 24010655
Cell phone: (+2) 01143050023
Call phone: (+2) 01024212175
E-mail: info@spc-eg.com
ليست هناك تعليقات:
إرسال تعليق